1. Academic Validation
  2. H2O2-Responsive Anticancer Prodrug: Synthesis, Precision Deuteration in Search of In Vivo Metabolites, and Activation Pathway

H2O2-Responsive Anticancer Prodrug: Synthesis, Precision Deuteration in Search of In Vivo Metabolites, and Activation Pathway

  • J Med Chem. 2025 Dec 11;68(23):25026-25037. doi: 10.1021/acs.jmedchem.5c01975.
Eron Saxon 1 Dana Stambekova 2 Thilini Nimasha Fernando Ponnamperumage 1 Joseph R Clark 3 Xiaohua Peng 1
Affiliations

Affiliations

  • 1 Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, 2000 E. Kenwood Boulevard, Milwaukee, Wisconsin 53211, United States.
  • 2 Department of Chemistry, Marquette University, 1414 W Clybourn St, Milwaukee 53233, Wisconsin, United States.
  • 3 Department of Chemistry, University of Tennessee, Knoxville, Tennessee 37996, United States.
Abstract

Boron-based Reactive Oxygen Species (ROS)-activated prodrugs offer a promising strategy for enhancing Cancer selectivity, yet their in vivo activation remains poorly defined. We report a novel H2O2-responsive phenylboronic nitrogen mustard prodrug (10a) and its precisely deuterated analogue (10b), designed to elucidate the activation pathway of ROS-responsive agents. These isotopologues differ only in ethyl substituents─hydrogen (10a) versus deuterium (10b)─enabling isotope-resolved tracking of metabolic transformations in vivo. Co-administration of 10a and 10b in triple-negative breast Cancer xenograft mice identified two metabolites, providing the first definitive in vivo evidence of oxidative deboronation as the primary activation mechanism. Prodrug 10a exhibited H2O2-inducible DNA-alkylating activity, selectively inhibited the proliferation of high ROS-expressing MDA-MB-468 Cancer cells over nonmalignant MCF-10A cells, markedly suppressed tumor growth without observable toxicity. This study highlights precision deuteration as a mechanistic probe and establishes a platform for rational design and optimization of boron-based Anticancer prodrugs.

Figures
Products